| Azacitidine-CHOP for Patients With Nodal T-cell Lymphoma With T-follicular Helper Phenotype (ACANTUS) (NCT05230680) | Won Seog Kim | 2022-07-01 |
| Efficacy and Safety of Chidamide Combined With BEAM Pretreatment Regimen in Autologous Transplantation for T-cell Lymphoma (NCT05367856) | Ruijin Hospital | 2022-05-28 |
| Intravenous Injection of Oncolytic Virus Injection (RT-01) in Patients With Relapsed or Refractory T-cell Lymphoma (NCT05387226) | The First Affiliated Hospital of Bengbu Medical University | 2022-05-01 |
| Understanding the Role of Large Extracellular Vesicles in Lymphomas and Lymphoproliferative Disorders: the "Off the Beaten Track" Liquid Biopsy (NCT06782854) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2022-02-21 |
| Tucidinostat, Azacitidine Combined With CHOP Versus CHOP in Patients With Untreated Peripheral T-cell Lymphoma (NCT05075460) | Peking Union Medical College Hospital | 2021-10-01 |
| Phase I Clinical Trial of Autologous CD7-CAR T Cell Therapy for High-risk Acute T-cell Leukemia/lymphoma (NCT04840875) | Beijing Boren Hospital | 2021-09-14 |
| Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma (NCT04712864) | Legend Biotech USA Inc | 2021-09-13 |
| Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies (NCT04264078) | Xinqiao Hospital of Chongqing | 2021-03-01 |
| BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) (NCT04752826) | BioInvent International AB | 2021-01-25 |
| CAR T-cells Against CD30 (HSP-CAR30) for Relapsed/ Refractory Hodgkin and T-cell Lymphoma. (NCT04653649) | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | 2020-09-29 |
| A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory T or B Cell Malignancies (COBALT-LYM) (NCT04502446) | CRISPR Therapeutics AG | 2020-07-31 |
| Duvelisib Maintenance After Autologous Stem Cell Transplant in T-Cell Lymphomas (NCT04331119) | Washington University School of Medicine | 2020-07-23 |
| CD4CAR for CD4+ Leukemia and Lymphoma (NCT03829540) | Huda Salman | 2020-07-09 |
| Study of Brentuximab Vedotin as Therapy After Autologous Stem Cell Transplant in Cluster of Differentiation Antigen 30 (CD30) Positive Peripheral TCell Lymphomas (NCT04334174) | University of Kansas Medical Center | 2020-05-29 |
| A Dose Escalation Study Evaluating CPI-818 in Relapsed/Refractory T-Cell Lymphoma (NCT03952078) | Corvus Pharmaceuticals, Inc. | 2019-05-03 |
| Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL) (NCT03792256) | Children's Oncology Group | 2019-04-11 |
| Safety and Efficacy of Tenalisib (RP6530) in Combination With Romidepsin in Patients With Relapsed/Refractory T-cell Lymphoma (NCT03770000) | Rhizen Pharmaceuticals SA | 2019-03-12 |
| Allo-HSCT as First-line Consolidation in High-risk PTCL (NCT03672084) | Peking University People's Hospital | 2019-01-01 |
| Total Body Irradiation +/- Total Lymphoid Irradiation & Anti-Thymocyte Globulin in Non-myeloablative Hematopoietic Cell Transplantation (NCT03734601) | Stanford University | 2018-11-05 |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells (NCT03628612) | Autolus Limited | 2018-08-02 |
| p53/p16-Independent Epigenetic Therapy With Oral Decitabine/Tetrahydrouridine for Refractory/Relapsed Lymphoid Malignancies (NCT02846935) | Yogen Saunthararajah | 2017-04-25 |
| Pembrolizumab for T/NK-cell lymphomasNK-cell Lymphomas (NCT03021057) | The University of Hong Kong | 2016-12-01 |
| A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL) (NCT02588651) | Deepa Jagadeesh | 2016-06-17 |
| Bendamustine, Carboplatin and Dexamethasone (BCD) for Refractory or Relapsed Peripheral T-cell Lymphoma (NCT02424045) | Samsung Medical Center | 2015-05-01 |
| Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma (NCT02309580) | Memorial Sloan Kettering Cancer Center | 2015-01-01 |
| Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma (NCT01902225) | Weiyun Ai | 2014-03-04 |
| A Phase II Study of Doxycycline in Relapsed NHL (NCT02086591) | University of Rochester | 2014-03-01 |
| Safety and Efficacy Study of a Dual PI3K Delta/Gamma Inhibitor in Hematological Malignancies (NCT02017613) | Rhizen Pharmaceuticals SA | 2013-11-01 |
| High Risk Adult T-cell Leukemia/Lymphoma (ATLL-HR) and Allogeneic Transplant (NCT01941680) | University Hospital Center of Martinique | 2013-10-31 |
| A Pilot Study of Oncaspar® + Dexamethasone in Patients With Relapsed or Refractory T-Cell Lymphoma (NCT01878708) | Dana-Farber Cancer Institute | 2013-07-01 |
| Study of IPI-145 in Combination With Rituximab or Bendamustine/Rituximab in Hematologic Malignancies (NCT01871675) | SCRI Development Innovations, LLC | 2013-05-01 |
| ECHELON-2: A Comparison of Brentuximab Vedotin and CHP With Standard-of-care CHOP in the Treatment of Patients With CD30-positive Mature T-cell Lymphomas (NCT01777152) | Seagen Inc. | 2013-01-31 |
| Helical Irradiation of Total Skin (HITS) for T Cell Lymphoma (NCT01854112) | Far Eastern Memorial Hospital | 2012-11-01 |
| Efficacy of a Treatment With CHOP and Lenalidomide in First Line in Angioimmunoblastic T-cell Lymphoma (AITL) (NCT01553786) | The Lymphoma Academic Research Organisation | 2011-11-01 |
| Trial of Endostar Combined With CHOPT for T Cell Lymphoma (NCT01430013) | Tianjin Medical University Cancer Institute and Hospital | 2011-06-01 |
| AMG 319 Lymphoid Malignancy FIH (NCT01300026) | Amgen | 2011-04-01 |
| Tandem Auto-Allo Transplant for Lymphoma (NCT01181271) | Massachusetts General Hospital | 2010-08-01 |
| A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients (NCT01561833) | Yale University | 2009-10-01 |
| Bendamustine in Patients With Refractory or Relapsed T-cell Lymphoma (NCT00959686) | French Innovative Leukemia Organisation | 2009-09-01 |
| Endostar Combined With CHOP Regimen as First Line Chemotherapy for Peripheral T Cell Lymphoma (NCT00974324) | Fudan University | 2009-08-01 |
| Intratumoral Poly-ICLC Plus Low Dose Local Radiation in Low Grade Recurrent B and T Cell Lymphoma (NCT00880867) | Nevada Cancer Institute | 2009-04-01 |
| Efficacy and Safety Study of Fostamatinib Disodium Tablets to Treat T-Cell Lymphoma (NCT00798096) | Rigel Pharmaceuticals | 2009-03-01 |
| A Study for Patients With Non-Hodgkin's Lymphomas (NCT00542919) | Eli Lilly and Company | 2007-11-01 |
| CD4 in Combination With CHOP in Treating Non-cutaneous Peripheral TCell Lymphoma (NCT00893516) | Emergent BioSolutions | 2007-05-01 |
| A Phase II Clinical Trial of Lenalidomide for T-cell Non-Hodgkin's Lymphoma (NCT00322985) | AHS Cancer Control Alberta | 2006-06-01 |
| HuMax-CD4 in Non-Cutaneous T-Cell Lymphoma (NCT00877656) | Emergent BioSolutions | 2005-08-01 |
| LAMPP Trial for Peripheral and Cutaneous T-Cell Lymphoma (NCT00161239) | University of Medicine and Dentistry of New Jersey | 2005-02-01 |
| Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma (NCT00161590) | Weill Medical College of Cornell University | 2004-07-01 |
| Investigation of the Human Immune Response in Normal Subjects and Patients With Disorders of the Immune System and Cancer (NCT00001582) | National Cancer Institute (NCI) | 1997-06-07 |